Page 1 | Search Results | Cancer Research | American Association for Cancer Research

1-16 of 16

Sort by

Sort Order Select

Journal Articles

Abstract 1809: Marizomib (NPI-0052) activity as a single agent in malignant glioma

Kaijun Di, Xing Gong, Dana M. Curticiu, Michael A. Palladino, Daniela A. Bota

Cancer Res (2014) 74 (19_Supplement): 1809.

https://doi.org/10.1158/1538-7445.AM2014-1809

Published: 01 October 2014

View article titled, Abstract 1809: Marizomib (NPI-0052) activity as a single agent in malignant glioma

Journal Articles

The proteasome inhibitor NPI-0052 reduces tumor growth and overcomes resistance of prostate cancer to rhTRAIL via inhibition of the NF-kβ pathway

Ana Maria Barral, Ta-Hsiang Chao, Sanaz Kanabolooki, Gordafaried Deyanat-Yazdi, Benjamin Nicholson, David McConkey, Michael A. Palladino, Saskia T.C. Neuteboom

Cancer Res (2007) 67 (9_Supplement): 1465.

Published: 01 May 2007

View article titled, The proteasome inhibitor NPI-0052 reduces tumor growth and overcomes resistance of prostate cancer to rhTRAIL via inhibition of the NF-kβ pathway

Journal Articles

The novel acanthoic acid analog, NPI-1387 inhibits tumor cell proliferation, reduces NF-κB DNA binding activity and functions upstream in the NF-κB signaling pathway

Ta-Hsiang Chao, Ana Maria Barral, Gordafaried Deyanat-Yazdi, Benjamin Nicholson, Venkat Macherla, G. Kenneth Lloyd, Kwang-Ok Lee, Young-Ger Suh, Michael A. Palladino, Saskia T C Neuteboom

Cancer Res (2006) 66 (8_Supplement): 896.

Published: 15 April 2006

View article titled, The novel acanthoic acid analog, NPI-1387 inhibits tumor cell proliferation, reduces NF-κB DNA binding activity and functions upstream in the NF-κB signaling pathway

Journal Articles

Pharmacodynamic profiling defines the significant biological activities of the novel proteasome inhibitor NPI-0052: Comparison with Velcade^® (Bortezomib)

Ta-Hsiang Chao, Dharminder Chauhan, Gordafaried Deyanat-Yazdi, Laurence Catley, Paul Richardson, G. Kenneth Lloyd, Saskia T. C. Neuteboom, Kenneth C. Anderson, Michael A. Palladino

Cancer Res (2006) 66 (8_Supplement): 1141.

Published: 15 April 2006

View article titled, Pharmacodynamic profiling defines the significant biological activities of the novel proteasome inhibitor NPI-0052: Comparison with Velcade® (Bortezomib)

Journal Articles

Novel NFκB inhibitors NPI-1342 / NPI-1387 and proteasome inhibitor NPI-0052 overcome resistance of pancreatic carcinoma to rhTRAIL

Sanaz Khanbolooki, Simona Pino, Robert Andtbacka, Ta-Hsiang Chao, Saskia Neuteboom, Michael A. Palladino, David J. McConkey

Cancer Res (2006) 66 (8_Supplement): 184.

Published: 15 April 2006

View article titled, Novel NFκB inhibitors NPI-1342 / NPI-1387 and proteasome inhibitor NPI-0052 overcome resistance of pancreatic carcinoma to rhTRAIL

Journal Articles

NPI-0052:Development of a novel orally available proteasome inhibitor

Ta-Hsiang Chao, Dharminder Chauhan, Benjamin Nicholson, Laurence Catley, Gordafaried Deyanat-Yazdi, G. Kenneth Lloyd, Saskia T. C. Neuteboom, Kenneth C. Anderson, Michael A. Palladino

Cancer Res (2005) 65 (9_Supplement): 1447–1448.

Published: 01 May 2005

View article titled, NPI-0052:Development of a novel orally available proteasome inhibitor

Journal Articles

Oral proteasome inhibitor (NPI-0052) enhances sensitivity to combination Gemcitabine and Erbitux in a pancreatic cancer xenograft model

James C. Cusack, Jr, Rong Liu, Lijun Xia, David Ljungman, Rena Bahjat, Michael A. Palladino, Jr

Cancer Res (2005) 65 (9_Supplement): 1167.

Published: 01 May 2005

View article titled, Oral proteasome inhibitor (NPI-0052) enhances sensitivity to combination Gemcitabine and Erbitux in a pancreatic cancer xenograft model

Journal Articles

NPI-2358, a novel tumor vascular disrupting agent

Benjamin Nicholson, Jamie Bishop, Yoshio Hayashi, Mary Ann Jordan, Leslie Wilson, Yoshiaki Kiso, Per Borgström, Michael A. Palladino, Saskia T. C. Neuteboom, G. Kenneth Lloyd

Cancer Res (2005) 65 (9_Supplement): 808.

Published: 01 May 2005

View article titled, NPI-2358, a novel tumor vascular disrupting agent

Journal Articles

Development of a structurally and biologically novel, oral proteasome inhibitor.

Brian Miller, Rena Bahjat, Ta-Hsiang Chao, Benjamin Nicholson, Saskia T. Neuteboom, G. Kenneth Lloyd, Michael A. Palladino, Jr

Cancer Res (2004) 64 (7_Supplement): 472.

Published: 01 April 2004

View article titled, Development of a structurally and biologically novel, oral proteasome inhibitor.

Journal Articles

NPI-2358, a novel diketopiperazine, induces tubulin depolymerization in vitro and tumor vascular collapse in vivo

Benjamin Nicholson, F. Rena Bahjat, Per Borgström, Saskia T. C. Neuteboom, Michael A. Palladino, Jr., G. Kenneth Lloyd

Cancer Res (2004) 64 (7_Supplement): 1250.

Published: 01 April 2004

View article titled, NPI-2358, a novel diketopiperazine, induces tubulin depolymerization in vitro and tumor vascular collapse in vivo

Journal Articles

Increased Transforming Growth Factor β Expression Inhibits Cell Proliferation in Vitro, yet Increases Tumorigenicity and Tumor Growth of Meth A Sarcoma Cells

Hsun-Lang Chang, Nancy Gillett, Irene Figari, Alfredo R. Lopez, Michael A. Palladino, Rik Derynck

Cancer Res (1993) 53 (18): 4391–4398.

Published: 01 September 1993

View article titled, Increased Transforming Growth Factor β Expression Inhibits Cell Proliferation in Vitro, yet Increases Tumorigenicity and Tumor Growth of Meth A Sarcoma Cells

Journal Articles

Circulating Cytokines in Patients with Metastatic Cancer Treated with Recombinant Interleukin 2 and Lymphokine-activated Killer Cells

Brett T. Gemlo, Michael A. Palladino, Jr., Howard S. Jaffe, Terje P. Espevik, Anthony A. Rayner

Cancer Res (1988) 48 (20): 5864–5867.

Published: 01 October 1988

View article titled, Circulating Cytokines in Patients with Metastatic Cancer Treated with Recombinant Interleukin 2 and Lymphokine-activated Killer Cells

Journal Articles

Comparison of Combinations of Interferons with Tumor Specific and Nonspecific Monoclonal Antibodies as Therapy for Murine B- and T-Cell Lymphomas

Teresa Y. Basham, Michael A. Palladino, Christopher C. Badger, Irwin D. Bernstein, Ronald Levy, Thomas C. Merigan

Cancer Res (1988) 48 (15): 4196–4200.

Published: 01 August 1988

View article titled, Comparison of Combinations of Interferons with Tumor Specific and Nonspecific Monoclonal Antibodies as Therapy for Murine B- and T-Cell Lymphomas

Journal Articles

Characterization of the in Vitro and in Vivo Species Preference of Human and Murine Tumor Necrosis Factor-α

Susan Mukavitz Kramer, Bharat B. Aggarwal, Thomas E. Eessalu, Susan M. McCabe, Bobbe L. Ferraiolo, Irene S. Figari, Michael A. Palladino, Jr.

Cancer Res (1988) 48 (4): 920–925.

Published: 01 February 1988

View article titled, Characterization of the in Vitro and in Vivo Species Preference of Human and Murine Tumor Necrosis Factor-α

Journal Articles

Expression of a Shared Tumor-specific Antigen by Two Chemically Induced BALB/c Sarcomas

Michael A. Palladino, Jr., Pramod K. Srivastava, Herbert F. Oettgen, Albert B. DeLeo

Cancer Res (1987) 47 (19): 5074–5079.

Published: 01 October 1987

View article titled, Expression of a Shared Tumor-specific Antigen by Two Chemically Induced BALB/c Sarcomas

Journal Articles

Characterization of Interleukin 2-dependent Cytotoxic T-Cell Clones: Specificity, Cell Surface Phenotype, and Susceptibility to Blocking by Lyt Antisera

Michael A. Palladino, Yuichi Obata, Elisabeth Stockert, Herbert F. Oettgen

Cancer Res (1983) 43 (2): 572–576.

Published: 01 February 1983

View article titled, Characterization of Interleukin 2-dependent Cytotoxic T-Cell Clones: Specificity, Cell Surface Phenotype, and Susceptibility to Blocking by Lyt Antisera

NARROW

Abstract 1809: Marizomib (NPI-0052) activity as a single agent in malignant glioma

The proteasome inhibitor NPI-0052 reduces tumor growth and overcomes resistance of prostate cancer to rhTRAIL via inhibition of the NF-kβ pathway

The novel acanthoic acid analog, NPI-1387 inhibits tumor cell proliferation, reduces NF-κB DNA binding activity and functions upstream in the NF-κB signaling pathway

Pharmacodynamic profiling defines the significant biological activities of the novel proteasome inhibitor NPI-0052: Comparison with Velcade^® (Bortezomib)

Novel NFκB inhibitors NPI-1342 / NPI-1387 and proteasome inhibitor NPI-0052 overcome resistance of pancreatic carcinoma to rhTRAIL

NPI-0052:Development of a novel orally available proteasome inhibitor

Oral proteasome inhibitor (NPI-0052) enhances sensitivity to combination Gemcitabine and Erbitux in a pancreatic cancer xenograft model

NPI-2358, a novel tumor vascular disrupting agent

Development of a structurally and biologically novel, oral proteasome inhibitor.

NPI-2358, a novel diketopiperazine, induces tubulin depolymerization in vitro and tumor vascular collapse in vivo

Increased Transforming Growth Factor β Expression Inhibits Cell Proliferation in Vitro, yet Increases Tumorigenicity and Tumor Growth of Meth A Sarcoma Cells

Circulating Cytokines in Patients with Metastatic Cancer Treated with Recombinant Interleukin 2 and Lymphokine-activated Killer Cells

Comparison of Combinations of Interferons with Tumor Specific and Nonspecific Monoclonal Antibodies as Therapy for Murine B- and T-Cell Lymphomas

Characterization of the in Vitro and in Vivo Species Preference of Human and Murine Tumor Necrosis Factor-α

Expression of a Shared Tumor-specific Antigen by Two Chemically Induced BALB/c Sarcomas

Characterization of Interleukin 2-dependent Cytotoxic T-Cell Clones: Specificity, Cell Surface Phenotype, and Susceptibility to Blocking by Lyt Antisera

Email alerts

AACR Journals

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only